70
Participants
Start Date
January 14, 2016
Primary Completion Date
May 31, 2018
Study Completion Date
May 31, 2018
Placebo
Granules for oral suspension (placebo)
Reldesemtiv 150 mg
Granules for oral suspension, 18.7% reldesemtiv
Reldesemtiv 450 mg
Granules for oral suspension, 56.0% reldesemtiv
Children's Hospital of Philadelphia, Philadelphia
Johns Hopkins Hospital Institute for Clinical and Translational Research Pediatric Clinical Research Unit, Baltimore
Duke University Medical Center, Durham
Nemours Childrens Hospital, Orlando
The Ohio State University Wexner Medical Center, Columbus
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
Children's Hospital Colorado, Aurora
The University of Utah, Clinical Neurosciences Center, Salt Lake City
UCLA, Los Angeles
University of California Irvine, Orange
Pediatric Neuromuscular Clinic Stanford University, Palo Alto
Hospital for Special Care, New Britain
Boston Children's Hospital, Boston
Alberta Children's Hospital, Calgary
Children's and Women's Health Centre of British Columbia, Vancouver
Children's Hospital - LHSC, London
Montreal Neurological Institute and Hospital, Montreal
Lead Sponsor
Astellas Pharma Global Development, Inc.
INDUSTRY
Cytokinetics
INDUSTRY